Clinical trials: Mixed Dyslipidaemia
Primary Hypercholesterolemia, Mixed Dyslipidemia
Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A
This is a multicenter, randomized, double-blind, active-controlled, parallel, phase III clinical trial to evaluate the efficacy and safety of combination therapy of DW5421A/DW5421B versus monotherapy of DW5421A in patients with…
- Trial name
- NCT07444762
- Testing
- DW5421A, DW5421B
- Where
- South Korea
- Volunteers
- 184 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Hyperlipidemia
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00349375
- Testing
- Fenofibrate/Simvastatin, Simvastatin
- Where
- 110 sites in Czechia, Denmark and 6 more
- Volunteers
- 1,040 people
- Sponsor
- Solvay Pharmaceuticals
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This is a multi-center, prospective, comparative and non-interventional cohort study involving two cohorts, one cohort (Inclisiran Cohort) of patients treated with inclisiran in certain special territories in China (eg.
- Trial name
- NCT05118230
- Testing
- Inclisiran
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Insulin Sensitivity, Lipoproteins Metabolism
Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia
Nicotinic acid (Niacin) has been used for many years for the treatment of dyslipidemia. Indeed Niacin decreases triglycerides (TG) and low density lipoprotein cholesterol (LDL-c) but more importantly increases high density…
- Conditions
- Insulin Sensitivity, Lipoproteins Metabolism, Non Esterified Fatty Acid Kinetics, Lipid Profile
- Trial name
- NCT01216956
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre de Recherche en Nutrition Humaine Rhone-Alpe
Dyslipidemia
Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
The objective of this study is To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameter from baseline after 12 weeks of treatment To evaluate the safety of PRC-4016 as…
- Trial name
- NCT01972178
- Testing
- PRC-4016, Statins
- Where
- 29 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pronova BioPharma
Cardiovascular, Metabolic Disease
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
- Trial name
- NCT07491172
- Testing
- CTX310
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- CRISPR Therapeutics AG
HIV Infections, Hyperlipidemia
Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART
HIV patients treated with Highly Active AntiRetroviral Therapy (HAART) show significant metabolic symptoms, such as lipodystrophy, dyslipidemia, and insulin resistance.
- Conditions
- HIV Infections, Hyperlipidemia, Exercise
- Trial name
- HIV (NCT00572429)
- Testing
- l-carnitine
- Where
- United States
- Sponsor
- University of California, Davis
Cardiovascular Diseases, Hyperlipidemias
The Mixed Meal Challenge Study
The purpose of this study is to assess sample collection conditions for various dietary challenges (fat, sugar, and mixed) and determine the optimal fasting and post-meal sample collection time points for future studies on a…
- Trial name
- NCT05087823
- Testing
- Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Emory University
Dyslipidemias, Hyperlipidemias
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered…
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Trial name
- NCT04516291
- Testing
- Vupanorsen
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Pfizer
Mixed Dyslipidemia
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
- Trial name
- NCT06932705
- Testing
- PA-111, PA-111A
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Dyslipidemias, Coronary Heart Disease
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal…
- Conditions
- Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
- Trial name
- NCT00639158
- Testing
- ABT-335, atorvastatin, ezetimibe
- Where
- 118 sites in United States
- Volunteers
- 543 people
- Sponsor
- Abbott
Hypercholesterolemia, Mixed Hyperlipemia
MK0859 Dose-Ranging Study (0859-003)
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- NCT00325455
- Testing
- MK0859
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipemia, Mixed
Study to Evaluate the Safety and PK of UI018
This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.
- Trial name
- NCT05085184
- Testing
- administration of UI018, co-administration of UIC201806 and UIC201602
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Hypercholesteremia, Hyperlipidemia
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the efficacy of MK0524 to improve the tolerability of extended-release niacin.
- Trial name
- NCT00376584
- Testing
- MK-0524A, ER Niacin
- Volunteers
- 825 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Dyslipidemia
The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines
The study is planned to show whether combined hypolipemic and antidiabetic therapy with various daily dosages influence the fasting plasma glucose, insulin sensitivity and proinflammatory cytokines in diabetic and dyslipidemic…
- Conditions
- Diabetes, Dyslipidemia, Inflammation, Cytokines
- Trial name
- MSF (NCT01101204)
- Testing
- Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
- Where
- Poland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Silesia
Hypercholesterolemia, Mixed Dyslipidemia
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2…
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Trial name
- BANTING (NCT02739984)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 424 people
- Sponsor
- Amgen
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
This is a multicenter, randomized, double-blind, placebo-controlled study in participants with primary hypercholesterolemia or mixed dyslipidemia, and elevated low density lipoprotein-cholesterol (LDL-C) to assess the efficacy…
- Trial name
- NCT01274559
- Testing
- Extended-release niacin/laropiprant (ERN/LRPT)
- Volunteers
- 1,173 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Hypertriglyceridemia
Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Trial name
- NCT00092560
- Testing
- MK0653, ezetimibe, Comparator: fenofibrate monotherapy
- Volunteers
- 587 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemiia, Mixed Dyslipidemia
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
- Trial name
- TRICONOS (NCT06686615)
- Testing
- Bempedoic acid, Ezetimibe, Rosuvastatin
- Where
- 163 sites in Austria, Belgium and 3 more
- Volunteers
- 2,000 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company